UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center

By Lara Goldstein

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS ) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD

You are viewing a robot-friendly page.Click hereto reload in standard format.